International Porphyrias Symposium (IPS) 2025
October 9-12, 2025 | Washington, D.C.
The material below is to support scientific exchange. Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Chronic symptoms reported by patients with acute hepatic porphyria in the POWER study in a subgroup analysis of nonrecurrent patients
Annualized attack rate reductions vs historical data and hemin use of patients with acute hepatic porphyria in phase 3 ENVISION trial who were not attack-free after 6 months of givosiran treatment
ENVISION study EQ-5D analysis to assess relationship between annualized attack rate with expanded criteria and chronic symptoms in patients with acute hepatic porphyria
The symptom and quality-of-life burden of Acute Hepatic Porphyria (AHP): Evidence from a systematic literature review
